Ischemia-modified albumin and fibulin-5 as diagnostic and prognostic markers for acute cerebrovascular disease

Abstract Background Fibulin-5 and ischemia-modified albumin (IMA) levels increase in acute phase of cerebrovascular diseases, yet data regarding their various stroke subtypes correlation with severity prognosis are still insufficient. This work aims to evaluate serum IMA fibulin-5 as markers for early detection predicting disease. Method case-control study was done on 100 patients first time stroke, assessed by the National Institute Health Stroke Scale (NIHSS) Glasgow Coma (GCS) within 24 h after event, lesion volume calculated, were measured few hours compared 75 control subjects. Three months later, modified Rankin (MRS). Results significantly higher patient than group positively correlated NIHSS score but inversely GCS score. statistically hemorrhage group, whereas infarction group. MRS at onset not IMA. Conclusion increased during only shows significant prognosis.